Darlington hospital drops in to help support the air ambulance - raising £10k
Woodlands Hospital, in Darlington, chose the air ambulance as its charity of the year for 2024 and raised £10,720 with a range of activities, including sponsorship of the charity ball, and Easter and Christmas fundraising extravaganzas.
The cheque was handed over to the life-saving charity during a celebration day for its commercial partners.
Woodlands, part of Circle Health Group, is now one of GNAA's commercial partners, with the hospital's logo displayed on the back of a critical care response vehicle for a year.
(Image: Woodlands Hospital) The hospital's long-serving Executive Director, Debbie Dobbs, said: 'The Great North Air Ambulance carries out priceless work in our region and, as a hospital embedded in the local community, it is a charity which aligns with our own values.
(Image: Woodlands Hospital)Recommended reading:
Darlington dad praises building society for support of childhood cancer research
First look at £13m County Durham housing development creating 30 jobs
Concerns over Darlington's child poverty "shame" affecting hundreds of families
'Our staff really embraced the charity and we are all thrilled to have broken the £10,000 mark for such a great cause.'
During the celebration day, supporters were thanked by Dean Abbott, whose life was saved by the air ambulance after a motorcycle accident in August 2010.
The hospital staff have chosen St Teresa's Hospice as their charity for 2025.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
23 minutes ago
- Yahoo
AstraZeneca therapy for clearing protein deposits fails main goal in late-stage study
By Pushkala Aripaka (Reuters) -AstraZeneca's experimental therapy anselamimab did not meet the main goal of a late-stage study for the treatment of a rare condition that causes a buildup of protein deposits in the body, the drugmaker said on Wednesday, sending shares down 1.3%. The study was assessing a combination of how often patients with advanced, heart-related AL amyloidosis were hospitalised for cardiovascular issues, and death from any cause over a period of time, when compared with placebo. While anselamimab did not achieve statistical significance for the overall population in the study, the therapy showed clinically meaningful improvement in a sub-group of patients, AstraZeneca said, without giving details of that group. JPMorgan analyst James Gordon said that he expects the study "failure in all comers to be seen as a minor negative," adding that while AstraZeneca did not give details of the subgroup in which anselamimab worked, he believes the drugmaker may pursue regulatory approval there. AL amyloidosis, also referred to as light chain or primary amyloidosis, leads to deposits of amyloid protein in the body because of defective plasma cells, and diagnosis is often delayed. All patients in the AstraZeneca study had received standard of care for the plasma defect, and anselamimab or a placebo was given on top of that. If left untreated, the accumulation of the deposits, particularly in the heart and kidneys, can progressively impair the quality of life causing organ damage and dysfunction, and lead to heart failure. "Anselamimab is the first and only investigational fibril depleter to show clinical benefit in AL amyloidosis, and these results underscore its potential to address a critical treatment gap in a prespecified subgroup of patients," said Marc Dunoyer, CEO of AstraZeneca's rare diseases unit, Alexion, which is developing the treatment. Anselamimab is a type of monoclonal antibody that binds itself to specific targets in the amyloid deposits and helps break them down. The company has forecast peak sales potential of $1 billion to $3 billion for the therapy, against overall annual sales of upwards of $50 billion. AstraZeneca said it was evaluating the complete data on anselamimab, adding that it plans to share data with health authorities.
Bloomberg
37 minutes ago
- Bloomberg
The Quest for a Hangover-Free Buzz
By David Nutt is an accomplished professor of neuropsychopharmacology at Imperial College London, but he hasn't always been great at reading a room. In 2009 he was the UK government's top adviser on drugs, a key voice on a council tasked with recommending changes to the nation's drug policies. That was until he argued that the field's greatest challenge, the substance responsible for the most widespread harm, was alcohol. While this would have been considered heresy in many societies, it proved to be an especially untenable position in Britain. He was asked to resign from his government post two days after he shared his views with the press. All these years later, Nutt is quick to clarify that he appreciates the upside of drinking. 'Most people meet their partners with the help of alcohol,' he says. 'It promotes sociability, and there's not much else like it.' What he's been after, he says, is a safer, healthier way to approximate the buzz of booze—something that can deliver the fun bits and skip the addiction, the cirrhosis, the sloppy aggro nonsense. By the time he was on the government council, research had made clear that the root of many problems with alcohol was its neurological complexity, that the good parts were intertwined with the bad ones. Once Nutt had more time on his hands, he decided to try making his own molecule, one that could give him the fuzzy feelings of a couple glasses of wine and leave it at that.
Forbes
37 minutes ago
- Forbes
Joonbyrd Rewrites The Unspoken Rules Of Clinical Beauty
Dr Alexis Granite, founder of clinical bodycare brand Joonbyrd Courtesy of Joonbyrd The Zoom call that changed Dr Alexis Granite's mind happened in her living room. Granite — a well-known dermatologist with nearly two decades of experience and the exceptionally rare distinction of holding dual US/UK medical licenses — was reviewing muted, clinical packaging mockups for her soon-to-launch skincare brand when her creative agency suddenly noticed something. Behind her on the video call was a room bursting with vibrant colors — quite the opposite to what they'd been developing. 'Wait a minute, like my living room is very, very colorful,' Granite recalls of that pivotal moment. 'And I was like, 'This is it!' I don't know why I'm hiding from what I love, which is color.' That realization became key to the eventual birth of Joonbyrd, a body-focused luxury skincare brand that challenges assumptions about what serious, clinical skincare should look like. Entering Joonbyrd's website and social accounts, and you'll be greeted with all pastel hues of the rainbow. And the brand identity is fully reflected in its product packagings: vibrant, textured, fun and simply joy-inducing — quite a stark contrast to the sterile designs adopted by most other expert-led brands in the industry. Joonbyrd's bodycare products are potent in active ingredients and designed to induce joy Courtesy of Joonbyrd The decision to embrace color wasn't just about aesthetic — it was deeply personal. Granite's approach to skincare has always been rooted in the joyful memories of sitting in her grandmother's bathroom, playing with 'all of her lotions and potions, their deliciously sweet smells.' This 'joyful nostalgia' that she associates with beauty became the foundation for what she terms 'Affective Wellness' — a holistic approach connecting emotional well-being with skincare. 'I've seen time and time again, day in and day out in my practice, how much skin and appearance, frankly, is tied to emotion and I truly believe that when you look good, you feel good,' Granite explains. With a six-month waiting list for her London-based practice and a patient roster she's known for years, she's witnessed firsthand how stress impacts skin conditions like acne, eczema, and rosacea, and wants to provide an element in her brand to address this factor. Speaking about perhaps her most counterintuitive decision on focusing solely on body care rather than facial skincare, Granite answers with a simple question: 'After all, why should the face have all the fun?' Kaleidoscope, Joonbyrd's most recently launched body serum, smells like a cherry pie topped with pink peonies Courtesy of Joonbyrd 'I was seeing more and more patients come in with body skin concerns and clocking that over time, particularly in recent years,' she notes, while also recognizing that many treatments have now moved 'below the chin.' The market gap was apparent. On one side were products focused purely on 'sensorial pleasure' — lovely bath salts and nice-smelling moisturizers without containing much of any active ingredients. On the other were clinical body products with 'that very sterile, quite medical feel.' Granite saw an opportunity: 'Why can't you have both? I want something that moisturizes amazingly, helps with crepey skin, improves keratosis pilaris bumps on the backs of the arms, but that also smells incredible.' After much testing and formulation, her vision materialized through Joonbyrd's proprietary ALXmd04™ technology, built on four pillars: hardworking actives typically reserved for facial skincare, microbiome support, botanical extracts, and functional enhancers including adaptogens that 'sense what your body needs.' Even the fragrance for each product is designed to evoke specific moods — the caramel latte body wash aims for playfulness, while the cashmere musk firming serum targets optimism. Fragrance and scent plays a big part in Joonbyrd's final products Courtesy of Joonbyrd The transition from practicing dermatologist to beauty entrepreneur was not without its challenges. 'Becoming a brand founder has been one of, if not the most challenging part of my career — the only rival being medical school,' Granite says with a laugh. Yet her medical training provided crucial preparation: 'My degree definitely set me up for the challenges that I've faced as a founder.' The biggest hurdle wasn't formulating products that delivered results — that came naturally after her consultancy/key opinion leader role over the past decade for brands like Kiehl's, SkinCeuticals, and CeraVe. Instead (and perhaps surprising to many,) it was convincing an industry accustomed to clinical aesthetics that serious skincare could also be joyful. 'I do think it is a bit more challenging to show the consumer that we're every bit as serious as a brand that doesn't look like us,' she acknowledges. With Joonbyrd's exclusive Sephora launch under her belt and the brand's new launches receiving rave reviews from consumers (the brand's newest Kaleidoscope, a body serum supercharged with incredible ingredients and smells like a cherry pie topped with pink peonies, is to die for), it would seem that Granite is finally shifting the unspoken rules and proving that clinical excellence and joy aren't mutually exclusive.
